Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie's shares dropped by 12% after its schizophrenia drug, emraclidine, failed in a phase II trial. This failure has raised concerns about the company's long-term neuroscience strategy. In the Huntington's disease space, companies like Prilenia and Wave Life Sciences are working on potential disease-modifying treatments, offering hope for a community that has faced disappointment in recent years. Rapt Therapeutics has crashed after liver injury concerns with its drug, and AstraZeneca and Amgen claim a late-stage win in chronic rhinosinusitis. The FDA has lifted a clinical hold on Novavax's COVID/flu vaccine candidates, while GSK has left the trade group BIO. Overall, the pharmaceutical industry is facing challenges and uncertainties as it continues to develop new treatments for various diseases.